Document Detail

Risk classification at the time of diagnosis differentially affects the level of residual disease in children with B-precursor acute lymphoblastic leukemia after completion of therapy.
MedLine Citation:
PMID:  12801533     Owner:  NLM     Status:  MEDLINE    
We have previously reported that children with B-precursor acute lymphoblastic leukemia (ALL) who remained in remission after successfully completing therapy had leukemia cells detectable by polymerase chain reaction (PCR) (N Engl J Med 1997;336(5):317-23). These patients were treated by an institutional protocol (P89-04) that lacked the post-remission intensification features of the contemporary Berlin-Frankfurt-Münster (BFM) based ALL protocols. In this report, we compared residual leukemia levels for patients on the P89-04 (n=15) and BFM-based Children's Cancer Group (CCG) studies (n=23) and for patients stratified according to risk group. Our goal was to establish which risk factors correlated with level of residual disease. Patients enrolled on the CCG protocols had lower levels of residual disease after completion of therapy than the P89-04 patients (P<0.019). Patients with high-risk disease also had lower levels of residual disease than patients with low risk disease (P<0.0001). Three-way analysis including time off treatment, risk group determined by features at presentation, and treatment protocol showed that risk group was the only significant independent variable (P<0.001).
M Fatih Okcu; W Mark Roberts; Dennis A Johnston; Maia V Ouspenskaia; Victor Z Papusha; Mark A Brandt; Theodore F Zipf
Related Documents :
3467143 - Abnormal nucleotide pattern in the eosinophils of a patient with acute lymphoblastic le...
3859713 - Defective chemotaxis and adherence in granulocytes from chronic myeloid leukemia (cml) ...
6983 - Breast sensation before and after plastic surgery.
Publication Detail:
Type:  Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  Leukemia research     Volume:  27     ISSN:  0145-2126     ISO Abbreviation:  Leuk. Res.     Publication Date:  2003 Aug 
Date Detail:
Created Date:  2003-06-12     Completed Date:  2003-08-08     Revised Date:  2009-11-03    
Medline Journal Info:
Nlm Unique ID:  7706787     Medline TA:  Leuk Res     Country:  England    
Other Details:
Languages:  eng     Pagination:  743-50     Citation Subset:  IM    
Texas Children's Cancer Center, Baylor College of Medicine, 6621 Fannin, CC 1510.00, Houston, TX 77030-2399, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Bone Marrow Examination
Genes, Immunoglobulin
Neoplasm, Residual* / diagnosis,  drug therapy,  etiology
Polymerase Chain Reaction
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / diagnosis*,  drug therapy
Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis*,  drug therapy
Remission Induction
Risk Assessment
Risk Factors
Time Factors

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Flt-3 and c-kit mutation studies in a spectrum of chronic myeloid disorders including systemic mast ...
Next Document:  The treatment of multiple myeloma with docetaxel (an ECOG study).